Intech Investment Management LLC Has $318,000 Stock Position in AxoGen, Inc. $AXGN

Intech Investment Management LLC grew its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 19.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,278 shares of the medical equipment provider’s stock after acquiring an additional 4,725 shares during the quarter. Intech Investment Management LLC owned about 0.06% of AxoGen worth $318,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of AxoGen by 3.3% during the second quarter. Geode Capital Management LLC now owns 1,060,599 shares of the medical equipment provider’s stock valued at $11,509,000 after acquiring an additional 33,686 shares during the last quarter. PNC Financial Services Group Inc. increased its position in AxoGen by 120.2% in the second quarter. PNC Financial Services Group Inc. now owns 8,077 shares of the medical equipment provider’s stock worth $88,000 after buying an additional 4,409 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of AxoGen by 53.3% in the second quarter. Acadian Asset Management LLC now owns 347,726 shares of the medical equipment provider’s stock valued at $3,772,000 after buying an additional 120,914 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of AxoGen by 11.3% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 378,170 shares of the medical equipment provider’s stock valued at $4,103,000 after buying an additional 38,459 shares during the period. Finally, First Eagle Investment Management LLC purchased a new position in shares of AxoGen during the 2nd quarter valued at $1,931,000. 80.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director William P. Mr. Burke sold 3,591 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $24.02, for a total transaction of $86,255.82. Following the completion of the transaction, the director owned 100 shares of the company’s stock, valued at approximately $2,402. This trade represents a 97.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 133,600 shares of company stock valued at $2,839,945. 2.78% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a report on Thursday, October 30th. Citizens Jmp increased their target price on AxoGen from $26.00 to $34.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating on shares of AxoGen in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of AxoGen in a research note on Tuesday, November 25th. Finally, JMP Securities set a $34.00 target price on AxoGen in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $28.86.

AxoGen Stock Up 1.6%

Shares of NASDAQ:AXGN opened at $29.00 on Monday. The stock has a market capitalization of $1.34 billion, a P/E ratio of -579.90 and a beta of 1.09. The stock’s 50-day moving average price is $20.75 and its 200-day moving average price is $15.65. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. AxoGen, Inc. has a 12-month low of $9.22 and a 12-month high of $28.99.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The firm had revenue of $60.08 million for the quarter, compared to analysts’ expectations of $56.90 million. AxoGen had a negative net margin of 0.98% and a negative return on equity of 1.96%. AxoGen has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that AxoGen, Inc. will post -0.29 earnings per share for the current year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.